Back to all bills
HR 2343119th CongressIntroduced
John W. Walsh Alpha-1 Home Infusion Act of 2025
Introduced: Oct 25, 2025
Standard Summary
Comprehensive overview in 1-2 paragraphs
The John W. Walsh Alpha-1 Home Infusion Act of 2025 amends Medicare to provide coverage and payment for Alpha-1 Antitrypsin Deficiency Disorder treatment under Part B, including home infusion therapy and related services.
Key Points
- 1Adds Alpha-1 Antitrypsin Deficiency Disorder treatment to Medicare Part B coverage
- 2Covers home-based augmentation therapy for eligible patients
- 3Provides payment for intravenous administration kits and nursing services
- 4Defines qualified home infusion therapy suppliers
- 5Effective date of January 1, 2027
Impact Areas
Rare disease treatment accessMedicare coverage expansionHome healthcare servicesAlpha-1 antitrypsin deficiency patientsInfusion therapy industry
Generated by kwaipilot/kat-coder-pro:free on Nov 21, 2025